Gene: SORCS1

114815
hSorCS
sortilin related VPS10 domain containing receptor 1
protein-coding
10q25.1
Ensembl:ENSG00000108018 MIM:606283 Vega:OTTHUMG00000019018 UniprotKB:Q8WY21
NG_029120.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.938e-1 (AD)  3.669e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs11193198chr10:107102209 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GRIA30.94
DRP20.939
ST8SIA30.936
ADAM230.934
DGKI0.933
RYR20.932
LONRF20.931
PRRG30.929
TANC20.929
CACNA1B0.928

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MYL3-0.543
COPZ2-0.54
HEY2-0.539
YES1-0.533
ASB4-0.5
RAB13-0.498
RAI14-0.498
MBNL3-0.496
CSAG1-0.496
RHOD-0.493

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of SORCS1 mRNA"23829299
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of SORCS1 mRNA"21394737
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of SORCS1 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SORCS1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SORCS1 mRNA"27188386
C006632arsenic trioxidearsenic trioxide results in decreased expression of SORCS1 mRNA26705709
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SORCS1 mRNA22316170
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SORCS1 mRNA15034205
C044887beta-methylcholinebeta-methylcholine affects the expression of SORCS1 mRNA21179406
C006780bisphenol Abisphenol A results in decreased expression of SORCS1 mRNA25181051
D002220CarbamazepineCarbamazepine affects the expression of SORCS1 mRNA25979313
D003471CuprizoneCuprizone results in increased expression of SORCS1 mRNA26577399
D004041Dietary FatsDietary Fats results in increased expression of SORCS1 mRNA25016146
C118739entinostatentinostat results in decreased expression of SORCS1 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
D007649KetamineKetamine results in decreased expression of SORCS1 mRNA20080153
D007854LeadLead affects the expression of SORCS1 mRNA28903495
C042720mercuric bromidemercuric bromide results in decreased expression of SORCS1 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SORCS1 mRNA27935865
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of SORCS1 mRNA27935865
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SORCS1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of SORCS1 mRNA26272509
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SORCS1 mRNA27935865
D011441PropylthiouracilPropylthiouracil results in increased expression of SORCS1 mRNA24780913
D018038Sodium SeleniteSodium Selenite results in decreased expression of SORCS1 mRNA18175754
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of SORCS1 mRNA15034205
D013750TetrachloroethyleneTetrachloroethylene results in decreased expression of SORCS1 mRNA28973375
D014212TretinoinTretinoin results in increased expression of SORCS1 mRNA23724009
C032910triadimefontriadimefon results in increased expression of SORCS1 mRNA26705709
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SORCS1 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of SORCS1 mRNA24935251
C012589trichostatin Atrichostatin A results in increased expression of SORCS1 mRNA24935251|2627250
D014635Valproic AcidValproic Acid affects the expression of SORCS1 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of SORCS1 mRNA24935251
D014635Valproic AcidValproic Acid results in increased expression of SORCS1 mRNA23179753|2493525
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of SORCS1 gene25560391
C581157XL147[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of SORCS1 mRNA27935865

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI12482870  
GO:0008188neuropeptide receptor activity-NAS11499680  
GO ID GO Term Qualifier Evidence PubMed
GO:0007218neuropeptide signaling pathway-NAS11499680  
GO ID GO Term Qualifier Evidence PubMed
GO:0016020membrane-IDA12482870  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26333835Using the Coriell Personalized Medicine Collaborative Data to conduct a genome-wide association study of sleep duration. (2015 Dec)Scheinfeldt LBAm J Med Genet B Neuropsychiatr Genet